­
Optibac-Babies

Why Optibac Babies & Children Offers The Best All-Round Support for Paediatric Health

Children’s health rarely sits in a single category. The same child who has eczema may also catch every cold attending the nursery; the toddler with poor iron status may also be the one struggling with constipation; the baby born by C-section may go on to develop atopic symptoms that follow them through childhood. Behind much of this is a hidden but extraordinarily influential community of trillions of microbes – the gut microbiome – which plays a central role in digestion, immunity, brain development, skin health, and long-term wellbeing. Supporting it has become one of the most evidence-based ways to give children the best possible start, and the most useful probiotic recommendations are the ones that work across multiple areas at once. It’s where Optibac Babies & Children comes in: a clinically researched, specialist probiotic formulated for the unique needs of infants and young children from birth to 12 years, designed to deliver all-round support across digestive health, immunity, atopy, antibiotic recovery, growth, and the foundational baby biome itself.

Setting the Scene: The First 1,000 Days and Beyond

The first 1,000 days of life – from conception through to the end of the second birthday – are arguably the most biologically influential window for future health. During this period, the gut microbiome is being seeded, shaped, and stabilised. It’s a remarkable biological handover: a baby is born with a relatively blank microbial slate, and within a few short years that slate becomes a complex, diverse ecosystem that will go on to influence digestion, nutrient absorption, immune modulation, neurological development, skin health, and even long-term risk of conditions including allergies, asthma, eczema, obesity, and metabolic disease. The choices made – and the disruptions encountered – in these first three years can quite literally shape a child’s health for life.

Several modern factors significantly influence how this microbial community develops. The most impactful are caesarean section births (which bypass natural microbial transfer), antibiotic exposure in pregnancy and first 1000 days, and formula feeding. A meta-analysis of 22,000 children has linked early antibiotic exposure to increased risk of atopic dermatitis, food allergies, wheezing, asthma, obesity, and several neurodevelopmental conditions28. Up to 70% of infants globally receive an antibiotic before their first birthday29, making this an issue that touches the majority of families – and one that pharmacy teams are uniquely placed to address through informed conversations about microbiome support.

Why Probiotic Support Continues to Matter Beyond Infancy

By around age three, the microbiome stabilises and begins to resemble a more adult-like profile – but research consistently shows the childhood microbiome remains distinct from an adult’s well into adolescence, with higher proportions of beneficial Bifidobacteria associated with immune resilience and gut health. This is why a specialist paediatric probiotic – rather than a generic adult product – remains the appropriate recommendation right through to age 12. It’s also why “the work isn’t done at age two”: children continue to face nursery and school exposure to viruses, courses of antibiotics, processed foods, and exam stress, all of which can disrupt the balance built during the first 1,000 days. Optibac Babies & Children is designed to span this entire developmental window – from birth right through to age 12 – in a single, parent-friendly format.

Common Childhood Health Challenges in Ireland

Walk into any community pharmacy in Ireland and the concerns parents raise are remarkably consistent: recurrent coughs and colds, ear infections, eczema flare-ups, tummy troubles, and worries about antibiotic courses. The Irish picture has some distinctive features: in 2024, 40.6% of all births in Ireland were by caesarean section5 – well above the European average; Ireland also has one of the highest childhood asthma rates globally, with around 10% of children affected6; and childhood eczema prevalence across the EU reaches up to 20%7. Middle ear infection (acute otitis media) adds to the picture – 85% of children have at least one episode by age three, half experience three or more, and globally AOM affects 709 million people per year1,2,4. These conditions share a common thread: they are all associated, to varying degrees, with early-life microbiome disruption – and all are areas where a well-formulated probiotic can make a meaningful, evidence-based contribution.

Meet Optibac Babies & Children

Optibac Babies & Children is a probiotic supplement specifically formulated for infants and children from birth to 12 years, featuring high-quality, clinically researched strains selected to support paediatric health and wellbeing. It is the brand’s dedicated children’s product, and it reflects more than two decades of focused research into friendly bacteria.

Each flavourless sachet provides:

  • 3 billion CFU of three clinically studied strains – Lactobacillus rhamnosus GG, Bifidobacterium breve M-16V®, and Lactobacillus rhamnosus HN001
  • 0.5g of prebiotic FOS fibre to help nourish beneficial bacteria
  • 2.5μg of Vitamin D to contribute to the normal function of the immune system

The sachets are vegetarian, flavourless, gluten-free, dairy-free, with no added sugars – making them suitable for a wide variety of dietary needs. They mix easily into infant milk, cool (non-acidic) foods, or drinks, and can be given to both breastfed and formula-fed infants. Breakfast is the preferred time for administration as part of a simple daily routine.

Why Bifidobacteria Are the Keystone of the Baby Biome

In a healthy breastfed infant, the gut is dominated by infant-type Bifidobacteria – species such as Bifidobacterium breve. These early colonisers are not just any beneficial bacteria; they are the architects of the infant gut. They make the gut more resistant to pathogen colonisation, support the maturation of the immune system, contribute to gut barrier development, and even improve responses to certain childhood vaccinations30. They are, quite simply, the keystone species around which the rest of the baby biome is built.

Crucially, not all Bifidobacterium strains are equally well-suited to the infant gut. Researchers now distinguish between Human-Residential Bifidobacteria (HRB) – species that are common natural inhabitants of the human gut and have evolved to thrive there – and non-HRB species, which are more typically found in animals or the wider environment. HRB species are genetically equipped to utilise human milk oligosaccharides (HMOs), the complex sugars in breast milk that effectively act as a prebiotic for these bacteria. Non-HRB species, including some commonly used in commercial dairy products, lack this metabolic machinery and don’t colonise the human gut as effectively30. For pharmacy teams making counter recommendations, this is a meaningful distinction: an infant probiotic built around HRB strains is biologically tailored to the very gut environment it’s meant to support.

The Three Clinically Researched Strains

Lactobacillus rhamnosus GG

L. rhamnosus GG is the world’s most researched probiotic strain, backed by more than 80 paediatric clinical trials in over 12,000 infants and children. It is endorsed by both the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) for paediatric acute gastroenteritis and antibiotic-associated diarrhoea, and by the World Gastroenterology Organisation (WGO) 2023 guidelines for acute paediatric diarrhoea8. Clinical research has investigated its role in inhibiting pathogens, reducing the risk of infections, reducing symptom severity and duration, reducing antibiotic use, and reducing time away from nursery or school. In one gold-standard trial of 281 children aged one to seven years attending day-care centres, those given 1 billion CFU of GG daily for three months over the winter period experienced fewer upper respiratory tract infections, a reduction in gastrointestinal infections, shorter bouts of illness, and reduced absence from day care compared with placebo9.

 

Bifidobacterium breve M-16V®

Originally isolated from a healthy human infant’s gut, it is backed by around 60 years of research, features in over 120 scientific studies including 36 paediatric clinical trials involving more than 4,000 infants, and is used in over 150 neonatal and baby care units worldwide. As an HRB Bifidobacterium, M-16V® is particularly well equipped to utilise the prebiotic HMOs in breast milk and the GOS/FOS fibres added to formula, meaning it is biologically designed to thrive regardless of feeding choice.

Clinically, M-16V® has been shown to increase Bifidobacteria levels, reduce pathogenic Enterobacteriaceae (associated with colic, eczema, asthma, and allergies), and support gut lining integrity by strengthening tight junctions10. In a randomised, double-blind trial of 290 formula-fed infants, supplementation with M-16V® plus prebiotic scGOS/lcFOS shifted the gut environment closer to that of breastfed infants – lowering faecal pH, raising L-lactate, and increasing the proportion of acetate (the dominant short-chain fatty acid in healthy breastfed infants), while also reducing detectable Clostridium difficile31. In a separate retrospective cohort study of 1,755 preterm neonates born before 34 weeks, routine M-16V® supplementation was associated with a reduction in necrotising enterocolitis (NEC ≥ Stage II) from 3% to 1% (adjusted odds ratio 0.43) and in the composite outcome of NEC or all-cause mortality from 9% to 5%11.

Lactobacillus rhamnosus HN001

HN001 is one of the most uniquely positioned probiotic strains in paediatric care: it is the only strain with a continuous evidence base spanning birth to age 11, demonstrating durable protection against atopic disease. In a landmark double-blind, placebo-controlled trial of 474 high-risk infants, HN001 supplementation from birth to 2 years halved the cumulative prevalence of eczema (HR 0.51)32. The protective effect persisted long after supplementation ended – still evident at age 4 (HR 0.57)33, age 6 (HR 0.56)34, and at age 11, where significant reductions were also seen in lifetime prevalence of wheeze (HR 0.76) and hay fever (RR 0.73)19. HN001 has even been shown to modify eczema risk in genetically susceptible children, partially overriding high-risk Toll-like receptor (TLR) genotypes35.

The Benefits: What the Evidence Shows

Collectively, the three strains have been researched in around 120 clinical trials involving approximately 17000 babies and children, with consistent benefits across the areas parents most often raise at the pharmacy counter.

Digestive Health

The digestive system is where probiotics were first studied and where the evidence for paediatric use remains especially strong.

  • Colic: The strains inhibit colic pathogens, and L. rhamnosus GG has been clinically proven to reduce excessive crying time by around 30 minutes a day12.
  • IBS: GG is one of the best-studied strains for reducing abdominal pain in children13.
  • Constipation: M-16V® softens stools, helping to reduce the risk of straining and constipation. In one trial of healthy full-term infants, parent-reported constipation was significantly lower with M-16V® formula vs standard formula (5% vs 27%)36, and a separate study reported less diaper dermatitis (OR 0.24)14.
  • Diarrhoea: GG may reduce the duration of diarrhoea associated with gastroenteritis15.

Immunity and Infections

This is perhaps the most compelling category for counter recommendations, particularly during the winter months, nursery settlings, or when a family is managing recurrent illness.

  • All three strains help to boost immune responses.
  • Infections: GG reduces the risk of upper respiratory tract, gastrointestinal, and ear infections16,17.
  • Fever duration: In a recent randomised, triple-blinded, placebo-controlled trial of 128 children with acute URTI and fever ≥38.5°C, a combination including  M-16V® and HN001, reduced the median duration of fever from approximately 5 days to 3 days – around two days shorter than placebo18.

A meta-analysis of randomised, placebo-controlled trials found that, compared with placebo, L. rhamnosus GG significantly reduced16:

  • Acute otitis media (AOM) by 35% (NNT 17)
  • Upper respiratory tract infections (URTIs) by 42% (NNT 4)
  • Antibiotic use by 23%

For a child who seems to catch every cold going round the nursery, or who is on their third course of antibiotics in a year, these are meaningful numbers. They also speak to the wider public health value of probiotic use in supporting antimicrobial stewardship.

Atopy: Eczema, Food Allergy, and Asthma

With approximately one in four children worldwide experiencing eczema, asthma, or another allergic condition, atopy is an increasingly common conversation at the pharmacy counter.

  • Eczema: All three strains may reduce the risk and symptom severity of eczema19,20,10
  • Cow’s Milk Protein Allergy (CMPA): In a meta-analysis of 10 RCTs and 853 children, those receiving GG were significantly more likely to develop tolerance to cow’s milk (RR 2.22)22, and to experience improved quality of life with food allergies20.
  • Asthma: M-16V® reduces the risk of asthma-like symptoms and use of asthma medication. In a placebo-controlled study of infants receiving 1 billion CFU daily for 12 weeks, frequent wheezing at the one-year follow-up was reported in just 13.9% of the probiotic group versus 34.2% of placebo, and asthma medication use was 13.9% versus 33.3%23.

Antibiotics Side Effects

Antibiotic courses are a common trigger for parents to seek a probiotic. The evidence here is robust:

  • Side effects: A meta-analysis of 12 RCTs (1,499 participants) found GG reduces the risk of antibiotic-associated diarrhoea (AAD) by approximately 51% (RR 0.49)24.
  • Antibiotic use: By supporting immunity, GG has been shown to reduce the overall need for antibiotics16.

Optibac Babies & Children can be taken alongside antibiotics – simply advise a two-hour gap between the antibiotic and the probiotic to allow each to work effectively. The dose can be increased to two sachets daily during antibiotic use or when clinically indicated.

Overall Wellbeing: Energy, Growth, and Iron Status

  • Anaemia: M-16V® may help improve iron levels in toddlers25 – a welcome finding given how common iron deficiency can be in the weaning-to-toddler transition.
  • Energy and growth: Efficient digestion and nutrient absorption increase the energy available for growth, and GG may support healthy growth rates in infants26.

Clinical Spotlight: M-16V® and Babies Born by C-Section

One of the most compelling areas of research for B. breve M-16V® relates to babies born by caesarean section – and in Ireland, where 40.6% of all 2024 births were by C-section5, this is a particularly relevant conversation. C-section born babies miss out on the natural microbial transfer that occurs during vaginal birth, and tend to have lower levels of beneficial bacteria, higher pathogen loads, and greater exposure to skin and hospital-type bacteria. A randomised, double-blinded, placebo-controlled trial by Chua and colleagues27 investigated whether M-16V® could help close that gap. The study supplemented 153 C-section born infants daily from birth to 16 weeks of age, comparing control milk, control milk plus prebiotic, and control milk plus prebiotic plus M-16V®, with vaginally born infants included as a natural comparator.

The findings were striking. Bifidobacteria levels increased in the probiotic group across all time points, reaching levels similar to those seen in vaginally born infants, while Enterobacteria (potential pathogens) were lower compared with control. In short, M-16V® accelerated Bifidobacteria colonisation in C-section born babies to levels seen in vaginally born infants, while simultaneously reducing pathogens – a finding with real implications for mitigating C-section-associated health risks later in life.

 

 

Practical Guidance for Pharmacy Recommendations

The dosage is straightforward: one sachet daily for general support, increasing to two during antibiotic use or when clinically indicated, with a two-hour gap between any antibiotic dose and the probiotic. The flavourless sachets mix easily into infant milk or cool, non-acidic foods and drinks (avoid hot foods, which can affect the live cultures), and breakfast is the preferred time for administration. Suitable from birth to 12 years, for both breast- and formula-fed infants. Vegetarian, gluten-free, dairy-free, with no added sugars, and no refrigeration required – convenient for busy family life and travel.

Who Is Optibac Babies & Children For?

Optibac Babies & Children is designed to support a broad range of children, from healthy infants whose parents are looking for a daily probiotic, to children managing specific health challenges. It is especially helpful for: babies born by caesarean section or formula-fed; children prone to colic, reflux, constipation, or other digestive discomfort; children attending nursery or school, where coughs, colds, and ear infections spread easily; families managing eczema, cow’s milk protein allergy, or asthma-like symptoms; children taking antibiotics or recovering from a course; and any parent simply looking to give their child a strong microbial foundation for life.

Why Pharmacy Teams Trust the Optibac Brand

Behind every sachet is a brand that has been quietly building credibility in the friendly bacteria category since 2004. Optibac is the UK and Ireland’s most trusted and recommended brand of friendly bacteria supplements, based on an independent consumer survey of 1,500 people (August 2025). The range is the most researched in the UK and Ireland, with strain-specific clinical evidence rather than generic genus-level claims. Optibac is also a recipient of the 2024 King’s Award for Enterprise for innovation, and operates with a strong commitment to eco-conscious and charitable practices alongside its scientific focus.

What to Remember

The childhood microbiome is one of the most important – and most influenceable – foundations of lifelong health, and the opportunity to support it continues throughout childhood. Optibac Babies & Children brings together three of the most clinically researched probiotic strains for paediatric use – L. rhamnosus GG, the HRB strain B. breve M-16V®, and L. rhamnosus HN001 – alongside prebiotic FOS fibre and vitamin D, in a flavourless sachet format suitable from birth to 12 years. With evidence spanning more than 120 clinical trials and 17,000 babies, and meaningful reductions demonstrated for AOM, URTIs, antibiotic use, fever duration, colic, eczema, asthma symptoms, and more, few paediatric probiotics offer this breadth of all-round, evidence-based support in a single daily sachet.

Recommend Optibac Babies & Children to support all-round health and wellbeing for children – from digestive comfort and immune resilience to skin health, growth, and the confidence of knowing you are giving them the best possible start.

References

  1. Gaddey HL, Wright MT, Nelson TN. Otitis media: rapid evidence review. American Family Physician. 2019;100(6):350-356.
  2. Venekamp RP, Damoiseaux RAMJ, Schilder AGM. Acute otitis media in children. BMJ. 2020;371:m4238.
  3. Johns Hopkins Medicine. Ear infections in babies and toddlers. Available at: hopkinsmedicine.org/health/conditions-and-diseases/ear-infections-in-babies-and-toddlers
  4. Mohanty S, Podmore B, Cuñado Moral A, et al. Incidence of acute otitis media from 2003 to 2019 in children ≤17 years in England. BMC Public Health. 2023;23:201.
  5. Healthcare Pricing Office (HPO), Ireland. Perinatal Statistics Report 2024. National caesarean section rate 40.6%.
  6. Asthma Society of Ireland / Health Service Executive. Childhood asthma prevalence data, Ireland.
  7. European Academy of Dermatology and Venereology / European Centre for Allergy Research Foundation. EU childhood eczema prevalence estimates.
  8. Guarner F, Sanders ME, Szajewska H, et al. World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics. February 2023. Also: ESPGHAN Working Group guidelines for paediatric acute gastroenteritis (2014, 2023 update) and antibiotic-associated diarrhoea (Szajewska H et al., JPGN 2016).
  9. Hojsak I, Snovak N, Abdović S, Szajewska H, Mišak Z, Kolaček S. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centres. Pediatrics. 2010;125(5):e1171-e1177.
  10. Wong CB, Iwabuchi N, Xiao J-Z. Exploring the science behind Bifidobacterium breve M-16V in infant health. Nutrients. 2019;11(8):1724.
  11. Patole SK, Keil AD, Nathan E, et al. Benefits of Bifidobacterium breve M-16V supplementation in preterm neonates – a retrospective cohort study. PLoS ONE. 2016;11(3):e0150775.
  12. Liu H, et al. Efficacy of Lactobacillus rhamnosus GG on infantile colic: clinical evidence. 2024.
  13. McFarland LV, Karakan T, Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome. 2021.
  14. Kosuwon P, Lao-Araya M, Uthaisangsook S, et al. A synbiotic mixture of scGOS/lcFOS and Bifidobacterium breve M-16V increases faecal Bifidobacterium in healthy young children. Beneficial Microbes. 2018;9(4):541-552.
  15. Szajewska H, Guarino A, Hojsak I, et al. Use of probiotics for the management of acute gastroenteritis in children: ESPGHAN update. Journal of Pediatric Gastroenterology and Nutrition. 2019.
  16. Liu S, Hu P, Du X, Zhou T, Pei X. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. Indian Pediatrics. 2013;50(4):377-381.
  17. Zuhair M, et al. Lactobacillus rhamnosus GG and paediatric infection prevention: updated meta-analysis. 2025.
  18. Bettocchi S, Comotti A, Elli M, et al. Probiotics and fever duration in children with upper respiratory tract infections: a randomized clinical trial. JAMA Network Open. 2025;8(3):e250669.
  19. Wickens K, Barthow C, Mitchell EA, et al. Early life supplementation with Lactobacillus rhamnosus HN001 reduces wheeze and hay fever to age 11. (Long-term follow-up of Wickens 2008 RCT). 2018.
  20. Xiaohua L, et al. Probiotic supplementation in paediatric atopic disease and food allergy: meta-analysis. 2025.
  21. Hulshof L, Van’t Land B, Sprikkelman AB, Garssen J. Exploring immune development in infants with moderate to severe atopic dermatitis. Frontiers in Immunology. 2018;9:630.
  22. Tan WF, Wei T, Zhao W, et al. Lactobacillus rhamnosus GG for cow’s milk allergy in children: a systematic review and meta-analysis. Frontiers in Pediatrics. 2021;9:727127.
  23. van der Aa LB, van Aalderen WMC, Heymans HSA, et al. Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis. Allergy. 2011;66(2):170-177.
  24. Hojsak I, Szajewska H, Canani RB, et al. Probiotics for the prevention of antibiotic-associated diarrhea in children: a systematic review and meta-analysis. Alimentary Pharmacology & Therapeutics. 2015;42(10):1149-1157.
  25. Chew C, Matsuyama M, Davies PSW, et al. A young child formula supplemented with a synbiotic mixture of scGOS/lcFOS and Bifidobacterium breve M-16V improves the gut microbiota and iron status in healthy toddlers. Frontiers in Pediatrics. 2024;12:1193027.
  26. Vendt N, Grünberg H, Tuure T, et al. Growth during the first 6 months of life in infants using formula enriched with Lactobacillus rhamnosus GG: double-blind, randomized trial. Journal of Human Nutrition and Dietetics. 2006;19(1):51-58.
  27. Chua MC, Ben-Amor K, Lay C, et al. Effect of synbiotic on the gut microbiota of cesarean-delivered infants: a randomized, double-blind, multicenter study. Journal of Pediatric Gastroenterology and Nutrition. 2017;65(1):102-106.
  28. Duong QA, Pittet LF, Curtis N, Zimmermann P. Antibiotic exposure and adverse long-term health outcomes in children: a systematic review and meta-analysis. Journal of Infection. 2022;85(3):213-300.
  29. Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatrics. 2014;168(11):1063-1069.
  30. Wong CB, Sugahara H, Odamaki T, Xiao JZ. Different physiological properties of human-residential and non-human-residential bifidobacteria in human health. Beneficial Microbes. 2018;9(1):111-122.
  31. Phavichitr N, Wang S, Chomto S, et al. Impact of synbiotics on gut microbiota during early life: a randomized, double-blind study. Scientific Reports. 2021;11:3534.
  32. Wickens K, Black PN, Stanley TV, et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 2008;122(4):788-794.
  33. Wickens K, Black P, Stanley TV, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clinical & Experimental Allergy. 2012;42(7):1071-1079.
  34. Wickens K, Stanley TV, Mitchell EA, et al. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitisation? Clinical & Experimental Allergy. 2013;43(9):1048-1057.
  35. Marlow G, Han DY, Wickens K, et al. Differential effects of two probiotics on the risks of eczema and atopy associated with single nucleotide polymorphisms to Toll-like receptors. Pediatric Allergy and Immunology. 2015;26(3):262-271.
  36. Harvey BM, Smith K, Brown J. Effects on growth and tolerance and hypoallergenicity of an amino acid-based formula with synbiotics. Pediatric Research. 2014;75(2):343-351.

For professional use only. Always consider a child’s individual medical history and speak to a pharmacist or GP if symptoms persist or worsen.

† Optibac is the brand of friendly bacteria supplements most trusted and recommended by UK and Irish consumers. See website T&Cs for survey details, 1,500 people, August 2025.